|
Gene: VMA21 |
Gene summary for VMA21 |
Gene summary. |
Gene information | Species | Human | Gene symbol | VMA21 | Gene ID | 203547 |
Gene name | vacuolar ATPase assembly factor VMA21 | |
Gene Alias | MEAX | |
Cytomap | Xq28 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q3ZAQ7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
203547 | VMA21 | P49T-E | Human | Esophagus | ESCC | 8.98e-15 | 1.73e+00 | 0.1768 |
203547 | VMA21 | P52T-E | Human | Esophagus | ESCC | 4.37e-35 | 8.57e-01 | 0.1555 |
203547 | VMA21 | P54T-E | Human | Esophagus | ESCC | 8.35e-14 | 3.66e-01 | 0.0975 |
203547 | VMA21 | P56T-E | Human | Esophagus | ESCC | 7.25e-07 | 9.77e-01 | 0.1613 |
203547 | VMA21 | P57T-E | Human | Esophagus | ESCC | 6.18e-10 | 2.62e-01 | 0.0926 |
203547 | VMA21 | P61T-E | Human | Esophagus | ESCC | 1.85e-16 | 4.23e-01 | 0.099 |
203547 | VMA21 | P62T-E | Human | Esophagus | ESCC | 9.45e-44 | 7.58e-01 | 0.1302 |
203547 | VMA21 | P65T-E | Human | Esophagus | ESCC | 3.07e-21 | 4.20e-01 | 0.0978 |
203547 | VMA21 | P74T-E | Human | Esophagus | ESCC | 4.11e-08 | 4.53e-01 | 0.1479 |
203547 | VMA21 | P75T-E | Human | Esophagus | ESCC | 3.49e-53 | 1.01e+00 | 0.1125 |
203547 | VMA21 | P76T-E | Human | Esophagus | ESCC | 3.02e-25 | 6.24e-01 | 0.1207 |
203547 | VMA21 | P79T-E | Human | Esophagus | ESCC | 2.45e-35 | 6.05e-01 | 0.1154 |
203547 | VMA21 | P80T-E | Human | Esophagus | ESCC | 2.98e-31 | 1.00e+00 | 0.155 |
203547 | VMA21 | P82T-E | Human | Esophagus | ESCC | 7.41e-07 | 6.84e-01 | 0.1072 |
203547 | VMA21 | P83T-E | Human | Esophagus | ESCC | 5.64e-41 | 1.18e+00 | 0.1738 |
203547 | VMA21 | P84T-E | Human | Esophagus | ESCC | 1.11e-08 | 7.14e-01 | 0.0933 |
203547 | VMA21 | P89T-E | Human | Esophagus | ESCC | 8.72e-23 | 1.28e+00 | 0.1752 |
203547 | VMA21 | P91T-E | Human | Esophagus | ESCC | 7.67e-15 | 1.61e+00 | 0.1828 |
203547 | VMA21 | P107T-E | Human | Esophagus | ESCC | 3.05e-56 | 1.40e+00 | 0.171 |
203547 | VMA21 | P126T-E | Human | Esophagus | ESCC | 1.13e-12 | 1.19e+00 | 0.1125 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00434627 | Esophagus | ESCC | regulation of ATPase activity | 30/8552 | 46/18723 | 5.91e-03 | 2.18e-02 | 30 |
GO:00700711 | Esophagus | ESCC | proton-transporting two-sector ATPase complex assembly | 12/8552 | 15/18723 | 7.31e-03 | 2.63e-02 | 12 |
GO:00434623 | Liver | Cirrhotic | regulation of ATPase activity | 21/4634 | 46/18723 | 1.61e-03 | 1.04e-02 | 21 |
GO:0070071 | Liver | HCC | proton-transporting two-sector ATPase complex assembly | 12/7958 | 15/18723 | 3.56e-03 | 1.59e-02 | 12 |
GO:004346211 | Liver | HCC | regulation of ATPase activity | 29/7958 | 46/18723 | 3.95e-03 | 1.74e-02 | 29 |
GO:00434626 | Oral cavity | OSCC | regulation of ATPase activity | 27/7305 | 46/18723 | 5.33e-03 | 2.07e-02 | 27 |
GO:00434628 | Skin | cSCC | regulation of ATPase activity | 22/4864 | 46/18723 | 1.16e-03 | 7.61e-03 | 22 |
GO:00700712 | Thyroid | PTC | proton-transporting two-sector ATPase complex assembly | 11/5968 | 15/18723 | 1.19e-03 | 6.84e-03 | 11 |
GO:00434629 | Thyroid | PTC | regulation of ATPase activity | 23/5968 | 46/18723 | 7.89e-03 | 3.33e-02 | 23 |
GO:007007111 | Thyroid | ATC | proton-transporting two-sector ATPase complex assembly | 11/6293 | 15/18723 | 1.94e-03 | 9.41e-03 | 11 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VMA21 | SNV | Missense_Mutation | c.202G>A | p.Ala68Thr | p.A68T | Q3ZAQ7 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A5-A0G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
VMA21 | SNV | Missense_Mutation | c.121N>A | p.Pro41Thr | p.P41T | Q3ZAQ7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
VMA21 | SNV | Missense_Mutation | c.287G>A | p.Arg96His | p.R96H | Q3ZAQ7 | protein_coding | deleterious(0.04) | possibly_damaging(0.511) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
VMA21 | SNV | Missense_Mutation | novel | c.264N>T | p.Trp88Cys | p.W88C | Q3ZAQ7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VMA21 | SNV | Missense_Mutation | novel | c.128G>A | p.Gly43Glu | p.G43E | Q3ZAQ7 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-BS-A0V4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VMA21 | SNV | Missense_Mutation | rs376099956 | c.226G>A | p.Val76Ile | p.V76I | Q3ZAQ7 | protein_coding | tolerated(0.08) | probably_damaging(0.984) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VMA21 | SNV | Missense_Mutation | rs140025330 | c.166N>A | p.Ala56Thr | p.A56T | Q3ZAQ7 | protein_coding | tolerated(0.42) | benign(0) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VMA21 | SNV | Missense_Mutation | c.65N>T | p.Ser22Leu | p.S22L | Q3ZAQ7 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-55-6982-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | gemzar | PD | |
VMA21 | SNV | Missense_Mutation | c.285G>T | p.Trp95Cys | p.W95C | Q3ZAQ7 | protein_coding | deleterious(0.01) | possibly_damaging(0.669) | TCGA-55-6987-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
VMA21 | SNV | Missense_Mutation | c.65N>T | p.Ser22Leu | p.S22L | Q3ZAQ7 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-97-7938-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |